Drugs / JH013
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06633055 | Oct 2024 → Jun 2025 overdue | — | Biotech Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JH013 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06633055 ↗ |
| Route | Subcutaneous | “JH013 injection, 2 subjects received placebo) were planned to be included in each dose group for subcutaneous administration.” NCT06633055 ↗ |